Qualigen TherapeuticsQLGN
Market Cap: $4.59M
About: Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.36% more ownership
Funds ownership: 5.41% [Q1] → 5.78% (+0.36%) [Q2]
0% more funds holding
Funds holding: 20 [Q1] → 20 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
39% less capital invested
Capital invested by funds: $110K [Q1] → $67.2K (-$42.4K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for QLGN.
Financial journalist opinion
Based on 3 articles about QLGN published over the past 30 days